Radiolabelled prostate-specific membrane antigen (PSMA) is increasingly used for the diagnosis (i.e., staging and restaging) and treatment of patients with prostate cancer. Radionuclide PSMA therapy is a useful new treatment […]
Radionuclide Theranostics is evolving and expanding in the field of nuclear medicine in various clinical settings. Its principle is based on therapeutic interventions after imaging to confirm the presence of […]
While PET imaging with radionuclides such as F18 and Ga68 have proven to provide high quality diagnostic imaging, imaging with other radionuclides can be more challenging. Zr-89 is one such […]
European School of Multimodality Imaging & Therapy (ESMIT)
Schmalzhofgasse 26
1060 Vienna
Austria
phone +43 1 890 44 27
e-mail esmit@eanm.org
